Genmab — September 2018
-
Det sker ikke så sjældent at auktionerne undervejs viser kurser helt hen i vejret, og som ikke bliver handlet. Det omvendte med enormt høje kurser kan også forekomme. Hvis Maia kommer efter fyraften, vil du på åbningsaktionen næste morgen kunne se kurser flere 100 kr over den kurs der faktisk bliver åbnet på.
-
God morgen :
-) -
Der er kommet medicinsk navn på HuMax-AXL-ADC: Enapotamab vedotin (http://www.genmab.com/product-pipeline/products-in-development/enapotamab-vedotin-humax-axl-adc
) -
-
En lille artikel om EV fra januar i år, "Targeting AXL: a promising new strategy for tumor treatment" https://sparringbioconsult.com/targeting-axl-a-promising-new-strategy-for-tumor-treatment/
-
Enig med Peter i at EV er optaget af Enfortumab Vedotin. https://www.urotoday.com/conference-highlights/asco-2018/asco-2018-bladder-cancer/104867-asco-2018-updated-results-from-the-enfortumab-vedotin-phase-1-ev-101-study-in-patients-with-metastatic-urothelial-cancer.html
-
i think we all sort of missed this at ASCO...? http://abstracts.asco.org/214/AbstView_214_209799.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind